NEW YORK, April 2 - Call it a love story born of supply and demand.

Despite their comparatively miniscule revenue base, publicly traded biotech companies, including genomics tool and tech firms, pay their CEOs considerably more than medical instrument or pharmaceutical companies, results of a recent survey show.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.